2024
Accessing breast cancer care in a protracted conflict: qualitative exploration of the perspectives of women with breast cancer in northwest Syria
Marzouk M, Hamze M, Debel J, Alshemali A, Alameen B, Bakkour M, Galal B, Chagpar A, Atassi B, Khoshnood K, Abbara A. Accessing breast cancer care in a protracted conflict: qualitative exploration of the perspectives of women with breast cancer in northwest Syria. Social Science & Medicine 2024, 117364. DOI: 10.1016/j.socscimed.2024.117364.Peer-Reviewed Original ResearchSyrian American Medical SocietyBreast cancer carePerspective of womenSemi-structured interviewsCancer careExperiences of accessing careBreast cancerAmerican Medical SocietyBreast cancer diagnosisAvailability of radiotherapyThematic saturationAccessing careHealthcare staffOncology careNorthwest SyriaPeer supportSocial supportThematic analysisClinical careFinancial strainMultiple intersectional challengesCancer diagnosisCareAccess diagnosisHospital records
2023
Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li F, Ferrucci L, Puklin L, Cao A, Nguyen T, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Tanasijevic A, Ligibel J, Irwin M. Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study. Journal Of Clinical Oncology 2023, 41: 5285-5295. PMID: 37656930, PMCID: PMC10691793, DOI: 10.1200/jco.23.00871.Peer-Reviewed Original ResearchConceptsRelative dose intensityPathologic complete responseProportion of patientsBreast cancerNeoadjuvant chemotherapyChemotherapy completionComplete responseNutrition interventionsHigher pathologic complete responseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerChemotherapy dose adjustmentsHome-based exerciseGrowth factor receptor 2Breast cancer outcomesEffects of exerciseFactor receptor 2Electronic medical recordsChi-square testUsual careDose intensityExercise interventionDose adjustmentRandomized trialsDoes Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery?
Cairns A, Chagpar A, Dupont E, Levine E, Gass J, Chiba A, Ollila D, Howard-McNatt M. Does Preoperative MRI Reduce Positive Margins after Breast-Conserving Surgery? Annals Of Surgical Oncology 2023, 30: 6053-6058. PMID: 37505353, DOI: 10.1245/s10434-023-13884-8.Peer-Reviewed Original ResearchConceptsPreoperative magnetic resonance imagingMagnetic resonance imagingExtensive intraductal componentMargin statusPositive marginsTumor sizeTumor factorsMedian tumor sizeBreast conserving surgeryBreast cancer managementInvasive lobular histologyNeoadjuvant chemotherapyLobular histologyIntraductal componentMedian ageMulticenter trialPatient agePalpable tumorsPatient factorsShave marginsNegative marginsResultsA totalAssociated FactorsBreast cancerUS Centers
2022
Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.Peer-Reviewed Original ResearchImmune-related adverse eventsTriple-negative breast cancerMultivariate logistic regression analysisPD-L1 statusLogistic regression analysisAA raceOverall survivalPathologic responseClinical trialsBreast cancerEarly-stage triple-negative breast cancerIncidence of irAEsPhase I/II trialPathologic complete response rateSignificant associationPhase I/II clinical trialsBaseline body mass indexSafety of immunotherapyWeekly nab-paclitaxelCharlson Comorbidity IndexComplete response ratePrimary efficacy endpointPD-L1 expressionBody mass indexBreast cancer recurrenceDoes perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer?
Chagpar A, Qader S, Baqri M, Khoshnood K, Ahmed H. Does perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer? Journal Of Clinical Oncology 2022, 40: e18680-e18680. DOI: 10.1200/jco.2022.40.16_suppl.e18680.Peer-Reviewed Original ResearchStage 1 diseaseBreast cancerStage diseaseStage 1 breast cancerHigher stage diseaseLate-stage diseaseStage of presentationCancer Stigma ScaleMonthly household incomeBCSS scoreMost patientsCancer patientsBreast centerPatientsStigma ScaleFeelings of shameFeelings of stigmaCancerDiseaseWomenPossible scoreMarital statusIraqi womenDiagnosisStage 1Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study.
Sanft T, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Ferrucci L, Puklin L, Nguyen T, Tanasijevic A, Neuhouser M, Hershman D, Basen-Engquist K, Jones B, Knobf M, Chagpar A, Silber A, Ligibel J, Irwin M. Randomized trial of diet and exercise on chemotherapy completion in women with breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) study. Journal Of Clinical Oncology 2022, 40: 12007-12007. DOI: 10.1200/jco.2022.40.16_suppl.12007.Peer-Reviewed Original ResearchRelative dose intensityHigh relative dose intensityBreast cancerDose-response effectPhysical activityPA interventionsNeoadjuvant chemotherapyChemotherapy completionDiet qualityStage I breast cancerEndocrine therapy adherenceTrial of dietDifferent chemotherapy regimensI breast cancerBody mass indexPatient-reported outcomesHealthy Eating IndexBetter diet qualityHigh physical activityMore physical activityElectronic medical recordsChi-square testUC participantsChemotherapy regimensSecondary endpointsThe Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients
Trant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.Peer-Reviewed Original ResearchConceptsTumor volumeBlack cohoshSitu patientsDuctal carcinomaAnti-inflammatory effectsTumor cellular proliferationBreast cancer treatmentCellular proliferationWilcoxon signed-rank testDCIS patientsAdverse eventsEligible subjectsWindow trialsCore biopsyInvasive diseaseKi67 expressionSigned-rank testBreast cancerGrade 3Hormone changesPatientsQuantitative immunofluorescenceBC extractSignificant toxicityCancer treatment
2021
Milestone Studies in Breast Cancer Surgery
Chagpar A. Milestone Studies in Breast Cancer Surgery. 2021, 9-17. DOI: 10.1007/978-3-030-73147-2_2.Peer-Reviewed Original ResearchBreast cancer surgeryCancer surgerySentinel node biopsyBreast-conserving surgeryPostoperative cosmetic outcomeBreast cancer managementAxillary dissectionNode biopsyRadical mastectomyLandmark trialsSurgical managementSurgical interventionCosmetic outcomeMargin clearanceBreast cancerCancer managementSurgeryRadiation oncologyMultidisciplinary approachOngoing studiesMilestone studyNumber of advancesMastectomyMorbidityAxillaImpact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.
Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.Peer-Reviewed Original ResearchBreast cancer survivorsWeight loss interventionSerum insulin levelsCancer survivorsLoss interventionPercent body fatSerum levelsSerum biomarkersTissue biomarkersBody compositionMonth 6Insulin levelsBreast tissueBreast cancerInsulin receptorBody fatStage I breast cancerBreast tissue levelsI breast cancerWeight loss trialBreast tissue markersLevels of CD163Breast tissue biopsiesUsual careLifestyle interventionHow did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2019
Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago.
Parkinson G, Chagpar A, Alleyne-Mike K, Nunez-Smith M, Zhou A, Servais L, Hofstatter E. Investigation of HBOC germline mutations in women diagnosed with breast cancer in Trinidad and Tobago. Journal Of Clinical Oncology 2019, 37: 6574-6574. DOI: 10.1200/jco.2019.37.15_suppl.6574.Peer-Reviewed Original ResearchFemale breast cancer patientsBreast cancer patientsNCCN criteriaCancer patientsGenetic counselingHigher breast cancer mortality ratesYounger ageHBOC testingBreast cancer mortality ratesOvarian cancer syndromeBreast cancer treatmentBreast cancer casesCancer mortality ratesYears of ageTesting servicesFurther genetic counselingPre-test counselingBreast cancer diagnosisNCCN guidelinesChart reviewFemale patientsOncology unitBreast cancerCancer casesFamily historyFactors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs).
Chagpar A, Coccia M. Factors associated with breast cancer mortality-per-incident case in low-to-middle income countries (LMICs). Journal Of Clinical Oncology 2019, 37: 1566-1566. DOI: 10.1200/jco.2019.37.15_suppl.1566.Peer-Reviewed Original Research
2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original ResearchSurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed Complex General Surgical Oncology 2018 DOI: 10.2310/7800.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgerySurgical Management of the Breast
Chagpar A. Surgical Management of the Breast. DeckerMed CGSO Case-Based Reviews 2018 DOI: 10.2310/cgso.16006.Peer-Reviewed Original ResearchSentinel node biopsySurgical managementAxillary dissectionNode biopsyBreast cancerBreast surgical oncologyKey clinical trialsNode-positive diseaseBreast-conserving surgeryCompletion dissectionBreast conservationRadical mastectomyClinical trialsSurgical oncologyRadiation therapyLeading malignancyCancerDissectionMastectomyBiopsyMalignancyKey wordsChemotherapyManagementSurgery
2017
Margins and Breast Cancer
Chagpar A. Margins and Breast Cancer. 2017, 59-69. DOI: 10.1007/978-3-319-60336-0_5.Peer-Reviewed Original ResearchPositive marginsBreast cancerComparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancerPathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.Peer-Reviewed Original ResearchPathologic complete response rateHER2-positive breast cancerDual HER2 blockadeComplete response ratePCR rateEstrogen receptorHER2 blockadeBreast cancerStage IResponse rateGrade 3/4 adverse eventsSymptomatic congestive heart failureClinical stage ICompletion of chemotherapyPhase II studyTaxane-based chemotherapyCongestive heart failureEfficacy of anthracyclinesPositive breast cancerNormal cardiac functionEntire treatment durationER- cancersER cohortNeoadjuvant pertuzumabWeekly paclitaxel
2016
Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer.
Ligibel J, Giobbie-Hurder A, Shockro L, Rhei E, Troyan S, Dominici L, Chagpar A, Frank E, McTiernan A, Yung R, Freedman R, Tolaney S, O'Connor K, Stecker K, Dillon D, Irwin M. Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer. Journal Of Clinical Oncology 2016, 34: 564-564. DOI: 10.1200/jco.2016.34.15_suppl.564.Peer-Reviewed Original Research
2015
Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011
Killelea B, Chagpar A, Horowitz N, Lannin D. Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011. Journal Of The American College Of Surgeons 2015, 221: e4. DOI: 10.1016/j.jamcollsurg.2015.08.310.Peer-Reviewed Original Research